Trial intelligence / Profile preview

Bosentan in pulmonary hypertension associated with sickle cell disease (ASSET-3)

NCT00360087Phase 3Terminated

Sponsor
Actelion Pharmaceuticals Ltd
Start
Mar 2006
Primary completion
Aug 2007
Modality
Nucleic Acid-Directed Small Molecules, Orthosteric Ligands
01

Overview

A Phase 3 trial of bosentan in pulmonary hypertension (PH), sponsored by Actelion Pharmaceuticals Ltd. Started Mar 2006; status: terminated.

02

Drugs

bosentan
03

Conditions

pulmonary hypertension (PH)

Beyond the preview

Go deeper on NCT00360087.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on NCT00360087.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call